Receptor phosphatases and cancer: Models for the therapeutic. Efficacy of somatostatin and LHRH analogues

C. Liebow, Angela Kamer

Research output: Contribution to journalArticle

Abstract

Analogues of two hormones, Somatostatin and LHRH, have been found to stimulate receptor mediated tyrodine phosphatase activity and reverse the growth promotion of the tyrosine kinase class of oncogenes. These receptors are induced during transformation due to their activation by the increased tyrosine kinase found in many cancers. The prevalence of tyrosine phosphatase stimulating receptors on many cancers suggests that these hormones, or their longer acting and more selective analogues, could have clinical efficacy in the treatment of sensitive tumors. A model is developed from existing observations integrating these receptor mediated tyrosine phosphatases into the general picture of control of cell growth.

Original languageEnglish (US)
Pages (from-to)200-207
Number of pages8
JournalCancer Journal
Volume5
Issue number4
StatePublished - 1992

Fingerprint

Somatostatin
Phosphoric Monoester Hydrolases
Gonadotropin-Releasing Hormone
Protein-Tyrosine Kinases
Hormones
Neoplasms
Growth
Oncogenes
Tyrosine
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Receptor phosphatases and cancer : Models for the therapeutic. Efficacy of somatostatin and LHRH analogues. / Liebow, C.; Kamer, Angela.

In: Cancer Journal, Vol. 5, No. 4, 1992, p. 200-207.

Research output: Contribution to journalArticle

@article{46d40bdc33e14ecfa9a21fc78da6fb04,
title = "Receptor phosphatases and cancer: Models for the therapeutic. Efficacy of somatostatin and LHRH analogues",
abstract = "Analogues of two hormones, Somatostatin and LHRH, have been found to stimulate receptor mediated tyrodine phosphatase activity and reverse the growth promotion of the tyrosine kinase class of oncogenes. These receptors are induced during transformation due to their activation by the increased tyrosine kinase found in many cancers. The prevalence of tyrosine phosphatase stimulating receptors on many cancers suggests that these hormones, or their longer acting and more selective analogues, could have clinical efficacy in the treatment of sensitive tumors. A model is developed from existing observations integrating these receptor mediated tyrosine phosphatases into the general picture of control of cell growth.",
author = "C. Liebow and Angela Kamer",
year = "1992",
language = "English (US)",
volume = "5",
pages = "200--207",
journal = "Cancer Journal",
issn = "0765-7846",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "4",

}

TY - JOUR

T1 - Receptor phosphatases and cancer

T2 - Models for the therapeutic. Efficacy of somatostatin and LHRH analogues

AU - Liebow, C.

AU - Kamer, Angela

PY - 1992

Y1 - 1992

N2 - Analogues of two hormones, Somatostatin and LHRH, have been found to stimulate receptor mediated tyrodine phosphatase activity and reverse the growth promotion of the tyrosine kinase class of oncogenes. These receptors are induced during transformation due to their activation by the increased tyrosine kinase found in many cancers. The prevalence of tyrosine phosphatase stimulating receptors on many cancers suggests that these hormones, or their longer acting and more selective analogues, could have clinical efficacy in the treatment of sensitive tumors. A model is developed from existing observations integrating these receptor mediated tyrosine phosphatases into the general picture of control of cell growth.

AB - Analogues of two hormones, Somatostatin and LHRH, have been found to stimulate receptor mediated tyrodine phosphatase activity and reverse the growth promotion of the tyrosine kinase class of oncogenes. These receptors are induced during transformation due to their activation by the increased tyrosine kinase found in many cancers. The prevalence of tyrosine phosphatase stimulating receptors on many cancers suggests that these hormones, or their longer acting and more selective analogues, could have clinical efficacy in the treatment of sensitive tumors. A model is developed from existing observations integrating these receptor mediated tyrosine phosphatases into the general picture of control of cell growth.

UR - http://www.scopus.com/inward/record.url?scp=0026758289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026758289&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0026758289

VL - 5

SP - 200

EP - 207

JO - Cancer Journal

JF - Cancer Journal

SN - 0765-7846

IS - 4

ER -